In recent weeks, Novo Nordisk has rolled out a higher-dose 7.2 mg Wegovy injection in the US at a lower monthly price than Eli Lilly’s competing Zepbound, while the European Medicines Agency has approved more flexible, higher-temperature delivery for Wegovy shipments across Europe.
Together, these changes strengthen Wegovy’s convenience and cost positioning in the obesity market at a time when oral GLP-1 competition and pricing pressures are intensifying.
We’ll now examine how this higher-dose, lower-priced Wegovy rollout could reshape Novo Nordisk’s investment narrative around GLP-1 growth and margins.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
To own Novo Nordisk today, you need to believe its GLP-1 obesity and diabetes franchise can keep converting huge unmet demand into durable profits despite intensifying price and oral-GLP-1 competition. The launch of lower-priced, higher-dose Wegovy and more flexible Wegovy delivery in Europe directly affects the key near term catalyst of obesity franchise growth, but also touches the biggest current risk: ongoing price pressure that could weigh on margins if cuts outpace volume gains.
Among the recent announcements, the FDA approval of Awiqli, the first once-weekly basal insulin, looks especially relevant. It broadens Novo Nordisk’s chronic metabolic portfolio at a time when Wegovy and Ozempic carry an increasingly heavy share of expectations, and it could help balance the company’s dependence on GLP-1 pricing and volume trends as investors watch how the Wegovy HD rollout plays through to growth and profitability.
Yet behind the new products and price cuts, investors should be aware that rising capital intensity and margin pressure could…
Read the full narrative on Novo Nordisk (it’s free!)
Novo Nordisk’s narrative projects DKK319.2 billion revenue and DKK103.2 billion earnings by 2029. This requires 1.1% yearly revenue growth and about DKK0.8 billion earnings increase from DKK102.4 billion today.
Uncover how Novo Nordisk’s forecasts yield a DKK309.77 fair value, a 31% upside to its current price.
CPSE:NOVO B 1-Year Stock Price Chart
Some of the most optimistic analysts were already penciling in DKK 455.5 billion of revenue and DKK 167.5 billion of earnings by 2028, but if execution missteps or rising launch and promotion costs persist alongside this week’s aggressive Wegovy pricing moves, your view on Novo Nordisk could end up very different from theirs, so it is worth comparing several competing narratives before you commit.
Explore 100 other fair value estimates on Novo Nordisk – why the stock might be worth just DKK309.77!
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com